1Sad S,Marcotte R,Mosmann T R.Cytokine-induced differentiation of precursor mouse CD8 + T cells into cytotoxic CD8+ cells secreting Th1 and Th2 cytokines[].Immunity.1995
2Porter D L,Roth M S,Lee S J,et al.Adoptive immunotheropy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic blone marrow transplantation[].Bone Marrow Transplantation.1996
3Mackinnon S,Papadopoulos E B,Carabasi M H,et al.Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separating of GVL responses from GVHD[].Blood.1995
4Porter D L,Roth M S,McGarigle C,et al.Induction of graft -versus-host disease as immunotherapy for relapsed chronic myeloid leukemia[].New England Journal of Homeopathy.1994
5Glass B,Vharek L,Zeis M,et al.Graft versus-leukemia activity can be predicted by natural cytotoxity against leukemia cells[].British Journal of Haematology.1996
6Carter L L,Dutton R W.Relative perforin-and Fas-mediatd lysis in T1 and T2 CD8 effector populations[].J Immunol.1995
7Teshima J,Hill G R,Pan L,et al.IL-11 sparates graft -versus-leukemia effects from graft -versus-host disease after bone marrow transplantation[].The Journal of Clinical Investigation.1999
8Barrett A J.Mechanisms of the graft versus-leukemia reaction[].Stem Cells.1997
9Fowler D H,Gress R E.Th2 and Tc2 cells in the reglation of GVHD, GVL and Graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma[].Leukemia and Lymphoma.2000
10Williams J F,Petrus M J,Writht J A,et al.Fas-mediated lysis of chronic lymphocytic leukemia cells: role of type I versus type Ⅱ cytokines and autologous FasL-expressing T cells[].British Journal of Haematology.1999
同被引文献11
1Morett L, Bottinob C, Ferlazzo G, et al. Surface receptors and functional interations of human natueal killer cells: from bench to the clinic[J]. Cell Mol Life Sci, 2003, 60(10): 2139-2146.
2Reardon DA. Wen PY. Therapeutic advances in the treatment of glioblastoma:rationale and potential role of targeted agents[J]. Oncologist, 2006, 11(2): 152-164.
3Teshima T, Hill GR, Pan L, et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation[J].J Clin Invest, 1999, 104(3): 317-325.
4Giver CR, Montes RO, Mittelstaedt S, et al. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cell while preserving graft-versus-leukemia effects[J]. Biol Blood Marrow Transplant, 2003, 9(10): 616-632.
5Collins R H, Shpilberg O, Drobyski W R,et al. Donor, leukocyte infusions in 140patients with relapsed malignancy after al1o genetic bone marrow transplantation [J].J Clin Oncol, 1997,15:433.
6Barnes D, Loutit J, Neal F, et al. Treatment of murine leukaemia with x - rays and bomologous bone marrow: preliminary communication[J]. Br. Med J, 1956,2:626-630.
7Poynton C H. T cell depletion in bone marrom transplantion [J]. Bone marrow transplantation,1988,3:265 -279.
8Marphy W J, Longd D L. The potentional role of N K cell in the separation of graft versus-host disease after allo genetic bone marrow transplantion [J]. Immunal Rev,1997,157:167.
